Previous close | 4.6300 |
Open | 4.6600 |
Bid | 4.0100 x 100 |
Ask | 4.0500 x 500 |
Day's range | 3.9300 - 4.7099 |
52-week range | 2.3600 - 6.7900 |
Volume | |
Avg. volume | 372,922 |
Market cap | 245.689M |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.1700 |
Earnings date | 30 Apr 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 11.75 |
Lyra Therapeutics ( NASDAQ:LYRA ) First Quarter 2024 Results Key Financial Results Net loss: US$22.5m (loss widened by...
Lyra Therapeutics (LYRA) delivered earnings and revenue surprises of -34.62% and 33%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
-- Phase 3 Results from ENLIGHTEN 1 Trial of LYR-210 in Chronic Rhinosinusitis (CRS) Expected in May --WATERTOWN, Mass., April 30, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory sinonasal implants for the treatment of chronic rhinosinusitis (CRS), today reported its financial results for the first quarter ended March 31, 2024 and provided a corporate update. “With results